Equities analysts expect SI-Bone Inc (NASDAQ:SIBN) to post earnings of ($0.36) per share for the current quarter, according to Zacks. Zero analysts have made estimates for SI-Bone’s earnings. SI-Bone reported earnings of ($0.30) per share during the same quarter last year, which would indicate a negative year over year growth rate of 20%. The firm is expected to report its next earnings report on Thursday, December 5th.
According to Zacks, analysts expect that SI-Bone will report full-year earnings of ($1.31) per share for the current financial year. For the next year, analysts expect that the firm will post earnings of ($0.64) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover SI-Bone.
SI-Bone (NASDAQ:SIBN) last posted its earnings results on Tuesday, August 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The firm had revenue of $16.32 million for the quarter. SI-Bone had a negative return on equity of 84.84% and a negative net margin of 46.59%.
Shares of NASDAQ:SIBN traded up $0.56 during trading on Friday, reaching $20.36. The company’s stock had a trading volume of 7,555 shares, compared to its average volume of 109,272. The company has a current ratio of 12.00, a quick ratio of 11.55 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $472.36 million and a PE ratio of -28.04. SI-Bone has a 12 month low of $14.08 and a 12 month high of $23.03. The firm’s 50 day simple moving average is $19.00 and its two-hundred day simple moving average is $18.20.
In other SI-Bone news, CEO Jeffrey W. Dunn sold 14,503 shares of SI-Bone stock in a transaction on Friday, September 13th. The shares were sold at an average price of $19.16, for a total value of $277,877.48. Also, CFO Laura Francis sold 2,518 shares of SI-Bone stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $17.92, for a total transaction of $45,122.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 760,587 shares of company stock worth $14,217,750. 38.80% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SIBN. Federated Investors Inc. PA lifted its stake in shares of SI-Bone by 111.4% during the first quarter. Federated Investors Inc. PA now owns 370,000 shares of the company’s stock worth $6,971,000 after buying an additional 195,000 shares during the period. Granite Investment Partners LLC acquired a new position in SI-Bone during the first quarter valued at $851,000. Wells Fargo & Company MN lifted its position in SI-Bone by 4.0% during the second quarter. Wells Fargo & Company MN now owns 465,846 shares of the company’s stock valued at $9,475,000 after purchasing an additional 18,030 shares during the period. Spark Investment Management LLC acquired a new position in SI-Bone during the first quarter valued at $872,000. Finally, Bank of America Corp DE acquired a new position in SI-Bone during the fourth quarter valued at $683,000. 45.49% of the stock is currently owned by institutional investors and hedge funds.
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Read More: Stocks Increasing Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.